Blog

NEW YORK, NY AND AUSTIN, TX / ACCESS Newswire / July 31, 2025 / Terra Innovatum Srl (“Terra Innovatum,” or the “Company”), a developer of micro-modular nuclear reactors, and GSR III Acquisition Corp. (Nasdaq:GSRT), a publicly traded special purpose acquisition company, today announced that they will participate at the 45^th Annual Canaccord Growth Conference in Boston on August 12-14, 2025.

Members of Terra Innovatum’s leadership team, Cesare Frepoli, Co-Founder, Chief Operating Officer & Director of Licensing, and Massimo Morichi, Partner, Chief Strategy Officer & Safeguards Director, will present live in a fireside chat on Aug 13, 2025, at 1:30pm ET. A webcast of the presentation will be accessible on the investors section of Terra Innovatum’s website at https://www.terrainnovatum.com/investors.

The leadership teams of Terra Innovatum and GSRT will be available for one-on-one investor meetings during the conference. To schedule a meeting, please reach out to a Canaccord representative or TerraIR@allianceadvisors.com.

ABOUT TERRA INNOVATUM & SOLO^TM

Terra Innovatum’s mission is to make nuclear power accessible. We deliver simple and safe micro-reactor solutions that are scalable, affordable and deployable anywhere 1 MWe at a time.

Terra Innovatum is a pioneering force in the energy sector, dedicated to delivering innovative and sustainable power solutions. Terra Innovatum plans to leverage cutting-edge nuclear technology through the SOLO™ Micro-Modular Reactor (SMR™) to provide efficient, safe, and environmentally conscious energy. With a mission to address global energy shortages, Terra Innovatum combines extensive expertise in nuclear industry design, manufacturing, and installation licensing to offer disruptive energy solutions. Committed to propelling technological advancements, Terra Innovatum and SOLO™ are dedicated to fostering prosperity and sustainability for humankind.

It is anticipated that SOLO™ will be available globally within the next three years. Conceptualized in 2018 and engineered over six years by experts in nuclear safety, licensing, innovation, and R&D, SOLO™ addresses pressing global energy demands with a market-ready solution. Built from readily available commercial off-the-shelf components, the proven licensing path for SOLO™ enables rapid deployment and minimizes supply chain risks, ensuring final cost predictability. Designed to adapt with evolving fuel options, SOLO™ supports both LEU+ and HALEU, offering a platform ready to transition to future fuel supplies.

SOLO™ will offer a wide range of versatile applications, providing CO2-free, behind-the-meter, and off-grid power solutions for data centers, mini-grids serving remote towns and villages, and large-scale industrial operations in hard-to-abate sectors like cement production, oil and gas, steel manufacturing, and mining. It also has the ability to supply heat for industrial applications and other specialized processes, including water treatment, desalination and co-generation. Thanks to its modular design, SOLO™ can easily scale to deliver up to 1GW or more of CO2-free power with a minimal footprint, making it an ideal solution for rapidly replacing fossil fuel-based thermal plants. Beyond electricity and heat generation, SOLO™ can also contribute to critical applications in the medical sector by producing radioisotopes essential for oncology research and cancer treatment.

To learn more, visit: www.terrainnovatum.com.

CONTACTS

Giordano Morichi
Partner, Chief Business Development Officer & Investor Relations
Terra Innovatum Srl
E: g.morichi@terrainnovatum.com
W: www.terrainnovatum.com

Anantha Ramamurti
President, Chief Financial Officer
GSR III Acquisition Corp
E: anantha@gsrspac.com
P: (949) 468-7434

Nicholas Hresko-Staab
Vice President
Investor & Media Relations
Alliance Advisors IR
E: TerraIR@allianceadvisors.com

IMPORTANT INFORMATION FOR SHAREHOLDERS

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or constitute a solicitation of any vote or approval.

In connection with their pending business combination, a Dutch public limited liability company (“Pubco”), GSR III Acquisition Corp. (“GSRT”) and Terra Innovatum s.r.l. (“Terra Innovatum” and, together with GSR III and Pubco, the “Registrant Parties”) have filed with the SEC a registration statement on Form S-4 (the “Registration Statement”), which includes a preliminary prospectus of Pubco relating to the offer of securities to be issued in connection with the business combination, and a preliminary proxy statement of GSRT to be distributed to holders of GSRT’s ordinary shares in connection with GSRT’s solicitation of proxies for a vote by GSRT’s shareholders with respect to the Business Combination and other matters described in the Registration Statement. The Registrant Parties also plan to file other documents with the SEC regarding the business combination. After the Registration Statement has been declared effective by the SEC, a definitive proxy statement/prospectus will be mailed to the shareholders of GSRT. INVESTORS OF THE REGISTRANT PARTIES ARE URGED TO READ THE REGISTRATION STATEMENT, THE PROXY STATEMENT/PROSPECTUS CONTAINED THEREIN (INCLUDING ALL AMENDMENTS AND SUPPLEMENTS THERETO) AND ALL OTHER DOCUMENTS RELATING TO THE BUSINESS COMBINATION THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE BUSINESS COMBINATION.

Investors will be able to obtain free copies of the proxy statement/prospectus and other documents containing important information about the Registrant Parties once such documents are filed with the SEC, through the website maintained by the SEC at http://www.sec.gov. In addition, the documents filed by GSRT may be obtained free of charge by written request to GSRT at 5900 Balcones Drive, Suite 100, Austin TX 78731.

PARTICIPANTS IN THE SOLICITATION

Each of the Registrant Parties, and their respective directors and executive officers, may be considered participants in the solicitation of proxies with respect to the potential transaction described in this communication under the rules of the SEC. Information about the directors and executive officers of GSRT is set forth in GSRT’s filings with the SEC. Information regarding other persons who may, under the rules of the SEC, be deemed participants in the solicitation of the shareholders in connection with the potential transaction and a description of their direct and indirect interests will be set forth in the Registration Statement (and will be included in the proxy statement/prospectus) and other relevant documents when they are filed with the SEC. These documents can be obtained free of charge from the sources indicated above.

FORWARD LOOKING STATEMENTS

The statements contained in this press release that are not purely historical are forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding our expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.

The forward-looking statements contained in this press release are based on our current expectations and beliefs concerning future developments and their potential effects on GSRT and the other Registrant Parties. There can be no assurance that future developments affecting GSRT and the other Registrant Parties will be those that we have anticipated. These forward-looking statements speak only as of the date this press release is delivered and involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the definitive agreements with respect to the Business Combination; (2) the outcome of any legal proceedings that may be instituted against GSRT, any of the Registrant Parties, the combined company or others following the announcement of the Business Combination and any definitive agreements with respect thereto; (3) the inability to complete the Business Combination due to the failure to obtain approval of the shareholders of GSRT or the SEC’s declaration of the effectiveness of the Registration Statement (which will include the proxy statement/prospectus contained therein) to be filed by the Registrant Parties or to satisfy other conditions to closing; (4) changes to the proposed structure of the Business Combination that may be required or appropriate as a result of applicable laws or regulations or as a condition to obtaining regulatory approval of the Business Combination; (5) the ability of Pubco to meet stock exchange listing standards following the consummation of the Business Combination; (6) the risk that the Business Combination disrupts current plans and operations of Terra Innovatum as a result of the announcement and consummation of the Business Combination; (7) the ability to recognize the anticipated benefits of the Business Combination,

which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (8) costs related to the Business Combination, including the reorganization described in the business combination agreement; (9) changes in applicable laws or regulations; (10) the possibility that the Registrant Parties or the combined company may be adversely affected by other economic, business, and/or competitive factors; (11) the amount of redemption requests made by GSRT shareholders and (12) other risk factors described herein as well as the risk factors and uncertainties described in the Form S-4 and GSRT’s other filings with the SEC, as well as any further risks and uncertainties to be contained in the proxy statement/prospectus filed after the date hereof. In addition, there may be additional risks that neither GSRT nor any of the other Registrant Parties presently know, or that GSRT or the other Registrant Parties currently believe are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward- looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made.

None of GSRT, the other Registrant Parties, or any of their respective affiliates, officers, employees or agents, makes any representation or warranty, either express or implied, in relation to the fairness, reasonableness, adequacy, accuracy, completeness or reliability of the information, statements or opinions, whichever their source, contained in this press release or any oral information provided in connection herewith, or any data it generates and accept no responsibility, obligation or liability (whether direct or indirect, in contract, tort or otherwise) in relation to any of such information. GSRT, the other Registrant Parties and their respective affiliates, officers, employees and agents further expressly disclaim any and all liability relating to or resulting from the use of this press release and any errors therein or omissions therefrom. Further, the information contained herein is preliminary, is provided for discussion purposes only, is only a summary of key information, is not complete and is subject to change without notice.

In addition, the information contained in this press release is provided as of the date hereof and may change, and neither GSRT nor the other Registrant Parties undertakes any obligation to update or revise any forward- looking statements, whether as a result of new information, inaccuracies, future events or otherwise, except as may be required under applicable securities laws.

SOURCE: TERRA INNOVATUM SRL

View the original press release on ACCESS Newswire

Kraig Higginson, Current Chairman of the Board, Appointed Interim CEO

ESTERO, FL / ACCESS Newswire / July 30, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (“Aspire” or the “Company”), developer of a multi-faceted patent-pending supplement delivery technology, today announced that the Company’s Board of Directors (Board) has appointed Kraig Higginson as interim Chief Executive Officer (CEO), effective July 24, 2025. Mr. Higginson serves as Chairman of the Board and previously served as CEO of Aspire for four years. Michael C. Howe has resigned as CEO and as a member of the Board. The Board thanks Mr. Howe for his contributions to the Company and plans to initiate a search for a permanent CEO.

“On behalf of the entire Board, I want to thank Michael for his contributions to the Company and wish him the very best in the future,” said Kraig Higginson, Interim Chief Executive Officer of Aspire. “I look forward to leading Aspire with the same level of commitment as if I were in the role permanently, with a goal of continuing to execute on maximizing the potential of Aspire’s powerful and differentiated drug delivery platform. We are fortunate to have a capable leadership team, and we will continue to focus on positioning the business for long-term success.”

The Company also announced the resignations of Mr. Gary E. Stein and Ms. Barbara Sher from the Board, effective immediately. The Aspire Board is very grateful for Mr. Steins’s and Ms. Sher’s outstanding service as members of the Board and for all of the thoughtful insights and valuable contributions they provided during their tenures.

In connection with this transition, the Board of Directors appointed Howard Doss, to serve as Director and Chairman of the Audit Committee of the Company, effective immediately.

Mr. Doss, age 71, has served as the Chief Financial Officer of PowerUp from August 2023 until February 2025. He is a seasoned chief financial officer and accountant. He served as Chief Financial Officer of Kernel Group Holdings, Inc. In 2021, he served as Chief Financial Officer of Aesther Healthcare Acquisition Corp., a special purpose acquisition company until it consummated its initial business combination in February 2023. He has also served as chief financial officer of Trade Health, Inc., an online marketplace for health traded on Nasdaq under the symbol “SCNX.” Mr. Doss has served in a variety of capacities with accounting and investment firms. He joined the staff of Seidman & Seidman (BDO Seidman, Dallas) in 1977 and in 1980 he joined the investment firm Van Kampen Investments, opening the firm’s southeast office in Tampa, Florida in 1982. He remained with the firm until 1996 when he joined Franklin Templeton. After working for the Principal Financial Group office in Tampa, Florida, Mr. Doss was City Executive for U.S. Trust in Sarasota, Florida, responsible for high-net-worth individuals. He retired from that position in 2009. He served as CFO and Director for Sansur Renewable Energy, an alternative energy development company, from 2010 to 2012. Mr. Doss has also served as President of Staradio Corp. since 2005. Mr. Doss is a member of the America Institute of CPA’s. He is a graduate of Illinois Wesleyan University.

About Aspire Biopharma, Inc.

Headquartered in Estero, Fl., Aspire Biopharma has developed a disruptive technology that can deliver supplements and drugs rapidly and precisely. For more information, please visit www.aspirebiolabs.com.

Safe Harbor Statement

Certain statements made in this communication are “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of words such as “estimate,” “projects,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “would,” “should,” “future,” “propose,” “potential,” “target,” “goal,” “objective,” “outlook” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the financial position, business strategy and the plans and objectives of management for future operations. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of Aspire’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the parties, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Aspire Biopharma Holdings, Inc.

Contact

PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.com

SOURCE: Aspire Biopharma Holdings, Inc.

View the original press release on ACCESS Newswire

CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission (EC) has granted marketing authorization for the updated formulation of the COVID-19 vaccine Spikevax®, targeting the SARS-CoV-2 variant LP.8.1, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals six months of age and older. This marketing authorization follows the Positive Opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). The authorization is valid in all 27 EU member states, as well as Iceland, Liechtenstein and Norway. Following the EC decision, doses will be available for eligible populations ahead of the 2025-2026 vaccination season.

“We appreciate the EC’s timely review and are pleased that our updated COVID-19 vaccine will be available to protect the public against currently circulating strains,” said Stéphane Bancel, Chief Executive Officer of Moderna. “COVID-19 continues to impact individuals and healthcare systems globally and we encourage people to speak to their healthcare providers about receiving an updated vaccine.”

The marketing authorization follows guidance from various global health authorities, which recommended that COVID-19 vaccines be updated to target the LP.8.1 strain for the 2025-2026 vaccination season.

Moderna’s COVID-19 vaccines have been generally well-tolerated. The most common solicited local adverse event for Moderna’s COVID-19 vaccines is injection site pain. The most common solicited systemic adverse events include headache, fatigue, myalgia and chills.

Additional regulatory applications for Moderna’s updated COVID-19 vaccines targeting LP.8.1 are under review around the world.

About Moderna

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.

Moderna’s mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

Spikevax®is a registered trademark of Moderna.

Moderna Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the availability of Moderna’s COVID-19 vaccines in EU Member State, Iceland, Liechtenstein and Norway; and the tolerability of Moderna’s COVID-19 vaccines. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this press release.

Moderna Contacts

Media:
Chris Ridley
Head of Global Media Relations
+1 617-800-3651
Chris.Ridley@modernatx.com

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.

View the original press release on ACCESS Newswire

NEW YORK, NY / ACCESS Newswire / July 30, 2025 / D. Boral ARC Acquisition I Corp. (the “Company”) today announced the pricing of its initial public offering of 25,000,000 units at a price of $10.00 per unit for total gross proceeds of $250,000,000. The units are expected to begin trading on The Nasdaq Global Market under the ticker symbol “BCARU” on July 31, 2025. Each unit consists of one of the Company’s Class A ordinary shares and one-half of one redeemable public warrant. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Once the securities comprising the units begin separate trading, the Company expects that its Class A ordinary shares and warrants will be listed on The Nasdaq Global Market under the symbols “BCAR” and “BCARW,” respectively. The offering is expected to close on August 1, 2025, subject to customary closing conditions.

The Company was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. While the Company may pursue an acquisition opportunity in any business, industry, sector or geographical location, the Company intends to identify and acquire a business where the Company believes its management teams’ and affiliates’ expertise will provide a competitive advantage, including the technology, healthcare, and logistics industries.

D. Boral Capital LLC is acting as sole book-running manager for the offering. The Company has granted the underwriters a 45-day option to purchase up to 3,750,000 additional units at the initial public offering price to cover over-allotments, if any, which, if exercised in full, would bring the total gross proceeds of the offering to $287,500,000.

The offering is being made only by means of a prospectus. When available, copies of the prospectus relating to the offering may be obtained from D. Boral Capital LLC: Attn: 590 Madison Avenue 39th Floor, New York, NY 10022, or by email at dbccapitalmarkets@dboralcapital.com, or by telephone at (212) 970-5150, or from the U.S. Securities and Exchange Commission’s (the “SEC”) website at www.sec.gov.

A registration statement on Form S-1 relating to these securities was declared effective by the SEC on July 30, 2025. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements,” including with respect to the Company’s initial public offering (“IPO”) and the gross proceeds thereof, the anticipated use of the net proceeds from the IPO and the search for an initial business combination. No assurance can be given that the offering discussed above will be completed on the terms described, or at all, that the net proceeds of the offering will be used as indicated or that the Company will ultimately complete a business combination transaction in the sectors it is targeting or at all. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and preliminary prospectus for the IPO filed with the SEC. Copies are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contact

John Darwin, Chief Financial Officer
Email: contact@arc-group.com

SOURCE: D. Boral Capital

View the original press release on ACCESS Newswire

NEW YORK CITY, NEW YORK / ACCESS Newswire / July 30, 2025 / New to The Street, the nation’s premier financial media platform for emerging public companies, proudly announces a major media partnership with NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI). Under this agreement, NeOnc will be featured in a 12-part national broadcast series, with exclusive monthly interviews airing on Bloomberg Television and Fox Business Network. The series will also include earned media distribution, commercial rotation across national networks, and outdoor billboard campaigns in the most visible financial corridors in the U.S.

This partnership launches at a pivotal time for NeOnc Technologies, following two significant corporate milestones:

• The signing of a Letter of Intent to acquire breakthrough intellectual property (IP) for brain cancer treatment, positioning the company at the forefront of neuro-oncology innovation;

• The execution of a $50 million definitive strategic partnership with Quazar Investment, accelerating NeOnc’s operational and clinical development roadmap.

Breakthrough Science Meets Breakthrough Exposure

The integrated media campaign includes:

• 12 Long-Form Network Broadcast Interviews from the Nasdaq and NYSE studios on Bloomberg TV and Fox Business as sponsored programming.

• More than 300 Monthly Commercial Spots across targeted investor and innovation-focused time blocks.

• Earned Media Coverage on major U.S. networks via NewsOut™, including CBS, NBC, and ABC affiliates.

• Iconic Billboard Placements in Times Square (Nasdaq Tower and Reuters Boards), NYC Financial District shelters, and premium taxi tops.

• Digital Amplification via YouTube and social platforms:

  • New to The Street TV Channel: youtube.com/@NewtotheStreetTV

  • NewsOut Channel: youtube.com/@newsoutchannel

Executive Commentary

“NeOnc is entering a new era, not only in terms of medical science but also visibility in the public markets. Their latest IP acquisition and $50 million partnership with Quazar reflect serious momentum,” said Vince Caruso, Founder and CEO of New to The Street. “We’re proud to provide a media platform that matches their global ambitions and innovations with real-world distribution, every month.”

About NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI)

NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas.

NeOnc’s lead therapeutics, NEO100™ and NEO212™, are currently in Phase II human clinical trials and advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California, consisting of issued patents and pending applications related to NEO100, NEO212, and other candidates from the NeOnc patent family for multiple uses, including oncological and neurological conditions.
To learn more, visit https://www.neonc.com.

About New to The Street

Since 2009, New to The Street has been a leading force in financial media, showcasing public and private companies through its unmatched mix of national television broadcasts, digital syndication, and social media reach. With over 3.2 million subscribers on the New to The Street TV YouTube channel and a combined following of more than 511,000 across LinkedIn, Facebook, Instagram, and X, the platform delivers consistent visibility to investors, industry leaders, and the general public.

New to The Street offers more linear “real TV” broadcast distribution than any other outlet in the space, with long-running placements across Bloomberg TV, Fox Business Network, and other national platforms. Its “Opportunities to Consider™” segments and in-depth executive interviews have become a trusted source for market-moving narratives, emerging growth stories, and thought leadership across finance, tech, biotech, and beyond.

Learn more:

• Website: https://www.newtothestreet.com

• YouTube: youtube.com/@NewtotheStreetTV

• NewsOut Channel: youtube.com/@newsoutchannel

Media Contact:

Monica Brennan
Head of Communications, New to The Street
Monica@NewToTheStreet.com

SOURCE: New To The Street

View the original press release on ACCESS Newswire

TaxBandits has released a free e-book, “Everything You Need to Know About Form 941,” to help small businesses simplify payroll tax filing and avoid penalties ahead of the July 31 Q2 deadline.

ROCK HILL, SC / ACCESS Newswire / July 30, 2025 / TaxBandits, an IRS-authorized e-file provider, released an informational Form 941 e-book to help small businesses struggling with the administrative burden of payroll taxes to meet the quarter 2 (Q2) Form 941 deadline on July 31.

Titled “Everything You Need to Know About Form 941,” the e-book is now available on the TaxBandits website.

“It can be difficult for small businesses, especially new ones, to learn the ins and outs of payroll taxes and Form 941. With the Q2 deadline this week, we are hearing from a lot of clients who are filing at the last minute. That’s why we created an all-in-one guide to help them understand, prepare, and file Form 941 before the deadline tomorrow,” said CEO of SPAN Enterprises Naga Palanisamy.

How This Guide Helps Businesses Ahead of the Crucial 941 Deadline

Small businesses have many responsibilities to juggle, and adding payroll taxes on top can make meeting deadlines difficult.

• The February 2025 National Small Business Association’s survey reported that 24% of small businesses handle payroll internally and that 10% spend 10 or more hours per month handling payroll taxes.

• And according to the Q2 2025 US Chamber of Commerce Small Business Index, over 40% of small businesses are reporting increased time spent on compliance.

If small businesses are unable to keep up with these burdens and they miss the deadline on July 31, they risk IRS penalties and complications, including 5% of the total tax due for every month the filing is late, up to 25%.

That’s why TaxBandits has released their new e-book, “Everything You Need to Know About Form 941.” It gives business owners a clear path forward-breaking down what to file, when to deposit and how to avoid errors.

Key Information Covered

This e-book concisely breaks down the key areas that are crucial to 941 reporting in six sections, including:

• Overview of Form 941: Explains what information is required on Form 941, who is required to file, and the exceptions.

• Form 941 Tax Deposit Requirements: Details tax deposit requirements based on tax liability, when to deposit the taxes, different deposit schedules, and how to deposit 941 taxes.

• Methods to File Form 941: Explains the differences between e-filing and paper filing and why the IRS recommends e-filing.

• About TaxBandits: Showcases the value in TaxBandits’ 941 e-filing solutions and provides a step-by-step guide on how to e-file Form 941 through TaxBandits.

• Consequences of Failing to Meet the 941 Deadline: Reveals the penalties and risks associated with filing or depositing late.

• How to Correct Errors on a Previously Filed Form 941: Mentions how to correct 941 forms filed with errors by using 941-X.

E-Book Implementation with TaxBandits’ Services

In addition to the e-book, TaxBandits offers a full suite of features designed to help last-minute filers meet today’s deadline with confidence:

• One-click zero reporting: This option allows filers with no tax liability to automatically fill out many fields on the return.
  Prefill functionality: Businesses that have filed before with TaxBandits can copy previous quarter information onto their Q2 return to save time and reduce data entry.

• Error prevention: The platform automatically checks return data against IRS business rules and flags potential issues before submission.
  Schedules included: Schedule B, Form 8974 and Form 941-V are automatically included when applicable. Schedule R is also available for aggregate filers.

• Built-in e-signature tools: Filers can e-sign using Form 8453-EMP or an Online Signature PIN directly within the platform.

• Real-time IRS updates: Businesses receive timely notifications when their return is accepted, rejected or requires further attention.

• No cost corrections: If the filers spot an error after submitting the return, they can make corrections and file a 941-X at no additional cost.

• Free retransmission: If the IRS rejects the form for any errors, filers can fix the errors and retransmit at no additional cost.

• Flexible payment methods: Payment options include Electronic Funds Withdrawal (EFW), EFTPS, credit/debit card or check/money order.

TaxBandits also recognizes that for high-volume filers, such as tax pros and aggregate filers, the deadline represents a significant challenge for gathering, evaluating and submitting large amounts of client data to the IRS.

To support these clients, TaxBandits offers additional features designed for efficiency, including: bulk data upload options, methods for requesting numerous client signatures at once and the ability to apply their e-signature to all client forms simultaneously. Additionally, their team members can be given access to a centralized account for easy task delegation.

“From small businesses to CPA’s filing for dozens of clients, everyone deserves a streamlined 941 filing experience. We will continue to create content like our e-book and our filing solutions so that one day, every filer has this experience,” said Palanisamy.

The e-book “Everything You Need to Know About Form 941” can be downloaded at this link. To file Form 941 before the July 31 deadline, click here.

About TaxBandits

TaxBandits is a SOC 2 Certified, IRS-authorized e-file provider dedicated to providing a simplified filing experience for businesses, service providers and tax professionals of every size. They specialize in Forms 1099, W-2, 940, 941, 1095-B, 1095-C and W-9.

About SPAN Enterprises

SPAN Enterprises is headquartered in Rock Hill, South Carolina, and has been developing industry-leading software tools for e-filing and business management solutions for over a decade. The SPAN portfolio of products includes TaxBandits, ACAwise, ExpressExtension, 123PayStubs and TruckLogics.

Direct all media inquiries to Marketing Manager Caleb Flachman at caleb@spanenterprises.com.

SOURCE: TaxBandits

View the original press release on ACCESS Newswire

With identity theft cases rising nationwide, more consumers are discovering unfamiliar accounts or inquiries on their credit reports. Petroff Amshen LLP explains how to respond effectively, protect your credit standing, and understand your legal rights – without falling into inaction or misinformation.

NEW YORK, NY / ACCESS Newswire / July 30, 2025 / When someone spots a suspicious account or collection on their credit report, it’s natural to panic – or worse, to do nothing. But as identity theft becomes increasingly sophisticated, knowing how to fix identity theft on your credit report has become an essential form of personal protection. At Petroff Amshen LLP, attorneys stress that recognizing the issue is only step one. Acting on it – properly and promptly – is what prevents long-term damage.

A Growing Problem with Real Financial Consequences

According to recent data, identity theft continues to trend upward. In 2025 Q1 alone, over 150,000 reports of credit card identity theft were filed across the U.S., along with 56,000 loan or lease fraud cases and 31,000 bank account-related thefts. These incidents aren’t isolated – they often start with small signals, like a sudden dip in credit score or a denial of credit based on unknown accounts.

Many of these cases go unaddressed simply because people don’t know what to do first.

Start by Getting the Full Picture

Before taking action, individuals need a clear view of what’s on their credit record. This means requesting copies from all three major credit bureaus – Experian, TransUnion, and Equifax – and reviewing them carefully. “In many cases, people are surprised to find several unauthorized inquiries or new accounts they’ve never opened,” said Serge F. Petroff, Founding Partner of Petroff Amshen LLP.

Once identity theft is confirmed, filing a report with the Federal Trade Commission (FTC) and creating an identity theft affidavit are key steps. These documents will help initiate the dispute process with credit bureaus and protect the victim’s legal position moving forward.

Dispute the Inaccuracies-But Don’t Stop There

Fixing identity theft on your credit report doesn’t stop at writing a letter. Under the Fair Credit Reporting Act (FCRA), consumers have the right to dispute inaccurate or fraudulent information – but credit bureaus are not always responsive on the first try. Victims may find that the same item reappears or that their disputes are dismissed without investigation.

“Legal support becomes essential when the system doesn’t work as it should,” added Petroff. “We’ve seen clients who followed all the right steps, yet the damage remained. That’s where we step in – to enforce their rights.”

Your Rights Are Stronger Than You Think

When facing credit damage from identity theft, it’s important to know that federal law is on your side. The FCRA mandates that both credit bureaus and the companies reporting information – data furnishers – must investigate valid disputes and remove false data promptly. If they fail to do so, legal action may be necessary.

Petroff Amshen LLP emphasizes that you do not have to wait for financial loss to seek help. As soon as fraudulent information appears on your identity theft credit report, you may have grounds for legal recourse, especially if prior disputes have been ignored or mishandled.

Prevention Is as Important as Repair

Fixing identity theft is reactive – but protecting yourself from repeat attacks is equally critical. Consumers are encouraged to freeze their credit, set up fraud alerts, and monitor accounts regularly. If a breach has already occurred, Petroff Amshen LLP urges individuals to store documentation safely and avoid communicating with suspected scammers.

“Identity theft isn’t a one-time threat,” Petroff warned. “Once your information is out there, it can be used again and again. But if you act early and document every step, you’re in a much better position-legally and financially.”

Stay Informed, Stay Protected

Petroff Amshen LLP encourages consumers to take identity theft seriously – even at the first signs of suspicious activity. For those who have experienced credit report fraud or had their disputes ignored, legal guidance may be the next necessary step.

To learn more about your rights or what actions you can take, follow Petroff Amshen LLP on social media:

Instagram: @petroffamshen

Facebook: Petroff Amshen LLP

LinkedIn: Petroff Amshen LLP | New York

SOURCE: Petroff Amshen LLP

View the original press release on ACCESS Newswire